Eicarg Finance

Only Business & Financial News


CRVS stock rises on hopes of drug similar to AbbVie's $21 Billion Imbruvica

Abbvie purchased Pharmacyclic's Imbruvica back in 2015 for $21 billion. Now some of the same developers of Imbruvica have shown similar results with a similar drug in T cell lymphomas. Smaller market, but still could yield $1 billion.
Yahoo-Zacks Img:Reuters
2023-05-16 12:15:30